Colorectal Cancer
Colorectal cancer (CRC), also known as bowel, colon, or rectal cancer, involves the development of cancerous tumors in the colon or rectum, often beginning as benign polyps that transform over time. Key symptoms include changes in bowel habits, blood in the stool, unexplained weight loss, and fatigue, with risk factors including age, lifestyle choices, and certain genetic disorders.
Health Outcomes
- Accelerated Recovery of Chemotherapy-Induced Myelosuppression
- Activated Wnt/Beta-Catenin Signaling
- Activated p53/BAX-Mediated DNA Damage Response
- Additive Antitumorigenic Effect
- Alleviated Histopathological Changes in the Colon
- Altered Colonic Microbial Communities
- Altered Dominant Microbial Community
- Altered Faecal Microbiota Profile
- Altered Fecal Butyrate Levels
- Altered Fecal Metabolite Levels
- Altered Gastrointestinal Microbial Communities
- Altered Microbial Phyla Abundance
- Altered Short-Chain Fatty Acid Production by Gut Microbiota
- Attenuated Apoptosis
- Cancer Treatment Support
- Colonization of Fibrolytic Bacteria
- Degraded Non-Digestible Carbohydrates
- Delayed Tumor Onset
- Disease Prevention
- Disrupted Gut Microbiota Distribution
- Diversified B-Cell Populations in the Colon
- Elevated ERK Levels in Intestinal Stem Cells
- Elevated Fecal Acidic Steroid Levels
- Elevated β-Catenin Levels in Intestinal Stem Cells
- Enhanced Adhesion to Colon Cells
- Enhanced Anticancer Capacity
- Enhanced Antitumor Immune Response
- Enhanced Antitumor Immunity
- Enhanced Beneficial Gut Microbiota
- Enhanced CD8+ T Cell Infiltration
- Enhanced Carcinogenic Heterocyclic Amine Transformation
- Enhanced Caspase-3 Activity
- Enhanced Cell Adhesion
- Enhanced Cell Adhesion Capacity
- Enhanced Cell Viability
- Enhanced Colon Bacterial Diversity
- Enhanced Colonic Mucosa Adhesion
- Enhanced Colorectal Homeostasis
- Enhanced Cytolytic Response of CD8+ T Cells
- Enhanced DNA Repair
- Enhanced Gastrointestinal Survival
- Enhanced Glycolysis Pathway Activation
- Enhanced Gut Microbiota
- Enhanced Health Promotion
- Enhanced Natural Killer Cell Activity
- Enhanced Natural Killer Cell Tumor Killing Activity
- Enhanced Natural Killer Cell Tumoricidal Activity
- Enhanced Pro-Apoptotic MAPK Signaling
- Enhanced Tumor-Targeted Drug Delivery
- Extended Survival Periods
- Genome Sequencing / Genome Characterization
- Identification of FDA Approved Drug Target Regulators
- Identified Colorectal Cancer Vaccine Antigen Candidates
- Improved Antitumor Response
- Improved Cell Viability
- Improved Chemotherapy Efficacy
- Improved Colonic Antioxidant Levels
- Improved Colonic Health
- Improved Colonic Histology
- Improved Colonic Microbial Diversity
- Improved Colonic Microenvironment
- Improved Colorectal Cancer Outcomes
- Improved Effectiveness in Cancer Treatment
- Improved Efficacy Rate
- Improved Fecal Microbiota Diversity
- Improved Gut Microbiome Health
- Improved Gut Microbiota Composition
- Improved Histopathological Indicators
- Improved Intestinal Cell Proliferation
- Improved Intestinal Microbiota Health
- Improved Karnofsky Performance Status
- Improved NK-Cell Cytotoxicity
- Improved Natural Killer Cell Activation
- Improved Natural Killer Cell Activity
- Improved Natural Killer Cell Tumoricidal Activity
- Improved Objective Response Rate
- Improved Oncolytic Virotherapy Efficacy
- Improved Overall Survival
- Improved Pathological Response
- Improved Progression-free Survival
- Improved Proliferative Capacity of Intestinal Cells
- Improved Remission
- Improved Resistance to Sodium Selenite
- Improved Response Rate
- Improved Response to Immune Checkpoint Inhibitor Therapy
- Improved Response to PD-1 Immunotherapy
- Improved Splenetic NK Cell Activity
- Improved Survival
- Improved Survival Rate
- Improved Survival Rate in Digestive Conditions
- Improved Therapeutic Potential
- Improved Treatment Response Rate
- Improved Tumor Response
- Increased Activation of Intestinal Stem Cells
- Increased Adhesion to Epithelia
- Increased Anti-Tumor Activity
- Increased Antiangiogenic Activity
- Increased Anticancer Activity
- Increased Anticancer Treatment Adherence
- Increased Apoptosis
- Increased Bacillus Species
- Increased Beneficial Organic Acid Levels
- Increased Binding of Carcinogenic Compounds
- Increased Bioavailability of Phenolics
- Increased Branched Chain Fatty Acids in Colonic Digesta
- Increased Butyrate Concentrations in Colonic Digesta
- Increased Butyrate Levels
- Increased Butyrate Production
- Increased Butyric Acid Levels
- Increased Butyric Acid Production
- Increased Cell Death
- Increased Cell Division
- Increased Cellular Adhesion
- Increased Chromosomal Instability
- Increased Colon Cancer Survival Rate
- Increased Colonic Conjugated Linoleic Acid Concentrations
- Increased Colonic Mucosa Adhesion
- Increased Colonic Mucosal Glutathione S-Transferase Levels
- Increased Crypt Depth
- Increased Cure Rate after Conventional Treatment
- Increased Epithelial Proliferation
- Increased Expression of Oxidation-Related Gene
- Increased Fecal Acidic Steroid Levels
- Increased Fecal Butyrate Levels
- Increased Fecal Butyric Acid Concentration
- Increased Fecal Cell Persistence
- Increased Fecal Immunological Biomarkers
- Increased Fecal Lactate Levels
- Increased Glycolysis Pathway Activity
- Increased Insulin-like Growth Factor-1 Level
- Increased Intestinal Crypt Survival
- Increased Intestinal Polyamine Levels
- Increased Intestinal Stem Cell Proliferation
- Increased Intratumoral Accumulation
- Increased Intratumoral CD8+ T-cell Expansion
- Increased Lesion Detection Rate
- Increased Levels of Beneficial Metabolites
- Increased Lgr5 Levels in Intestinal Epithelium
- Increased MUC-2 Levels
- Increased Metabolic Activity in the Colon
- Increased Mitogenic Activity
- Increased NK Cell Activity
- Increased Natural Killer Cell Proportion
- Increased Number of Persistent Diseased Sites
- Increased Peroxidase Activity
- Increased Polyamine Production
- Increased Population of Clostridium Histolyticum
- Increased Pro-apoptotic Factor Levels
- Increased Protease Activity
- Increased Protective Fecal Bifidobacteria
- Increased Reduced Glutathione Level
- Increased Relative Abundance of Bifidobacterium Animalis
- Increased Relative Survival Percentage
- Increased SCFA Production
- Increased Short Chain Fatty Acids
- Increased Short-Chain Fatty Acid Production
- Increased Survival Rate
- Increased Survival Time
- Increased Survival in Tumor-Bearing Mice
- Increased Telomere Length
- Increased Tissue Invasion
- Increased Total Fecal SCFAs
- Increased VEGF Level
- Increased mTORC1 Activation
- Induced Glycolysis Pathway in Gastrointestinal Tract
- Induction of Specific CD8+ T Cells
- Inhibited Changes in Short-Chain Fatty Acids
- Inhibited EGF Receptor Signaling
- Inhibited Epithelial-Mesenchymal Transition
- Inhibited PI3K-Akt-mTOR Signaling
- Inhibited PI3K/AKT Pathway
- Lack of Long-Term Colonization of Bifidobacteria Strains
- Maintained Colorectal Homeostasis
- Maintained Fecal Short Chain Fatty Acid Levels
- Maintained Gut Microbiome Composition
- Maintained Intestinal Barrier Function
- Maintained Intestinal Microbiota Balance
- Maintained Natural Killer Cell Activity
- Maintained Viability in Presence of Bile Salts
- Moderate Impact on Main GI Bacterial Groups
- Modification of Gastrointestinal Microbiome
- Modulated Diurnal Short-Chain Fatty Acid Production
- Modulated Gut Microbial Diversity
- Modulated Intestinal Metabolite Profile
- Modulated Intestinal Microbial Community
- Modulation of Colon Epithelium by Lactate
- Neutralized Reactive Oxygen Species
- No Improvement in Objective Cancer Treatment Response
- No Mutagenicity
- No Serious Treatment-Related Adverse Events
- Non-Toxicity to Normal Colon Cells
- Overall Treatment Success
- Promotion of Healthy Gut Microbial Colonization
- Protection Against Induced Colon Cancer
- Protection Against Intestinal Epithelial Injury
- Reduced AOM-Induced Small Aberrant Crypt Foci (Combined Administration)
- Reduced AOM-Induced Small Colonic Aberrant Crypt Foci
- Reduced AQP8 Expression in Colon
- Reduced Abdominal Surgery Incidence
- Reduced Aberrant Crypt Foci Formation with Combined Administration
- Reduced Aberrant Crypt Foci Incidence
- Reduced Aberrant Crypt Foci Induced by Azoxymethane
- Reduced Aberrant Crypt Formation
- Reduced Aberrant Crypt Number
- Reduced Aberrant Crypts
- Reduced Abnormal Colonic Lesions
- Reduced Acute Radiation Enteritis Severity
- Reduced Apoptosis Due to Carcinogens
- Reduced Apoptosis of Colon Epithelial Cells
- Reduced Bax/Bcl-2 Ratio
- Reduced Bowel Toxicity-Related Hospital Care
- Reduced Butyrate Production
- Reduced CEA Levels
- Reduced Cancer Activity
- Reduced Cancer Progression
- Reduced Cancer Risk
- Reduced Cancer-Related Inflammation
- Reduced Cancer-Specific Mortality
- Reduced Carcinogen-Induced Large Aberrant Crypt Foci (ACF)
- Reduced Carcinogenesis
- Reduced Carcinogenic Activity of Intestinal Flora
- Reduced Caspase-3 Activity
- Reduced Cause-Specific Mortality
- Reduced Cell Adhesion
- Reduced Cell Apoptosis
- Reduced Cell Viability
- Reduced Chemotherapy Side Effects
- Reduced Chemotherapy-Induced Diarrhea
- Reduced Colon Cancer Marker Proteins
- Reduced Colon Cancer Tumor Growth
- Reduced Colon Length
- Reduced Colon Tumor Incidence
- Reduced Colonic Aberrant Crypt Foci
- Reduced Colonic Pathology
- Reduced Colony Formation of CRC Cells
- Reduced Colorectal Cancer Risk Associated with Ulcerative Colitis
- Reduced Colorectal Tumorigenesis
- Reduced Crypt Cell Proliferation
- Reduced DNA Damage
- Reduced Dysbiosis-Associated Bacteria Growth
- Reduced E. coli Activity
- Reduced Enterotoxigenic Bacteroides fragilis (ETBF) Levels
- Reduced Epithelial Cell Apoptosis
- Reduced Epithelial-Mesenchymal Transition
- Reduced Expression of Beta-Catenin
- Reduced Expression of STAT3-Dependent Tumor-Associated Genes
- Reduced Fas Level
- Reduced Fecal Bacterial Enzyme Activity
- Reduced Fecal Hydrogen Sulfide Emissions
- Reduced Fecal Mutagenicity
- Reduced Ferritin Level
- Reduced Folic Acid Level
- Reduced Fumonisin B1 Levels
- Reduced Fusobacterium Abundance
- Reduced Fusobacterium Nucleatum Levels
- Reduced Gastric Polyamine Levels
- Reduced Gastrointestinal Toxicity
- Reduced Genotoxicity
- Reduced Growth of CRC Xenograft
- Reduced IkappaB Alpha Degradation
- Reduced Incidence of Aberrant Crypts
- Reduced Incidence of Aberrant Crypts Relative to Aberrant Crypt Foci
- Reduced Incidence of Colon Cancer
- Reduced Incidence of Large ACF
- Reduced Incidence of Large Aberrant Crypt Foci
- Reduced Innate Immune Cell Activation
- Reduced Intestinal Apoptosis
- Reduced Intestinal Epithelial Apoptosis
- Reduced Intestinal Tumor Development
- Reduced Large Aberrant Crypt Foci
- Reduced Length of Hospitalization
- Reduced Lipid Peroxidation in Colonic Mucosa
- Reduced Metabolic Functions of Intestinal Microbiota
- Reduced Percentage of Bacteroidaceae in Gut Microbiota
- Reduced Production of Carcinogenic Enzymes
- Reduced Proportion of Fusobacteria
- Reduced Pulmonary Metastasis
- Reduced Putrefactive Short-Chain Fatty Acids
- Reduced Radiation-Associated Diarrhea
- Reduced Radiological Damage in the Gut
- Reduced Reactive Oxygen Species Formation
- Reduced Recurrence Rate
- Reduced Recurrence Risk
- Reduced Risk of Cancer
- Reduced Ruminococcus Abundance
- Reduced Severity of Colon Lesions
- Reduced Short-Chain Fatty Acids (SCFA)
- Reduced Small Aberrant Crypt Foci
- Reduced Survival Rate
- Reduced Swede Score
- Reduced Tumor Downstaging
- Reduced Tumor Formation
- Reduced Tumor Grade
- Reduced Tumor Growth
- Reduced Tumor Growth Rate
- Reduced Tumor Incidence
- Reduced Tumor Multiplicity
- Reduced Tumor Risk
- Reduced Tumor Stage
- Reduced Tumor Volume
- Regulated Host Epithelial Cells
- Regulated miR-130a-5p Levels
- Restored Mucin-2 Levels
- Reversed Toxin-Induced Inhibition of Protein Synthesis in Colonic Cells
- Selective Anti-Colon Cancer Activity
- Shifted Tumor-Associated Macrophages Toward Pro-Inflammatory M1 Polarization
- Suppressed Tumor Growth
- Targeted Tumor Reduction
- Unchanged Stool Frequency
- Upregulated Macrophage Inhibitory Factor